SAN DIEGO, July 30, 2019 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call
to discuss financial results and business highlights for the second
quarter ended June 30, 2019, as
follows:
Date
|
Tuesday August 6,
2019
|
Time
|
11:00 a.m.
EDT
|
Dial-in
numbers
|
(866) 503-5561 (U.S.
toll-free) or (253) 336-2965
|
Passcode
|
1953988
|
Webcast (live and
archived)
|
www.evofem.com under
"Investors" or click here
|
If participating by phone, please dial in approximately 10
minutes prior to the start of the call.
A slide presentation related to the call will be available via
the aforementioned webcast link on the Evofem website
https://evofem.investorroom.com/investors-home. Please connect to
the website at least 15 minutes prior to the call to allow for any
software download that may be necessary.
A replay of the teleconference will be available approximately
two hours after completion through Sunday, August 11, 2019,
at (855) 859-2056 (U.S.) or (404) 537-3406
(International). The replay access code is 1953988. The
archived webcast will be available via the aforementioned URLs
for one year.
About Evofem Biosciences
Evofem Biosciences, Inc., is
a clinical-stage biopharmaceutical company committed to developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health. Evofem Biosciences aims to
advance the lives of women by developing innovative solutions, such
as woman-controlled contraception and potential protection from
certain sexually transmitted infections ("STIs"). The Company
is leveraging its proprietary Multipurpose Vaginal pH Regulator
(MVP-R™) platform to develop Amphora® (L-lactic acid, citric acid
and potassium bitartrate) for birth control and prevention of
urogenital acquisition of certain STIs. For more information,
please visit www.evofem.com.
About Amphora
Amphora is an investigational MVP-R™
designed to regulate vaginal pH within the normal range of 3.5 to
4.5. This maintains an acidic environment which is inhospitable to
sperm as well as certain viral and bacterial pathogens associated
with sexually transmitted infections but is integral to the
survival of healthy bacteria in the vagina. Amphora met the
pre-specified primary endpoint of AMPOWER, the Phase 3 clinical
trial evaluating this MVP-R for the prevention of pregnancy in
approximately 1,400 women at 112 centers in the United States. In this clinical trial,
Amphora had a favorable safety profile and was well tolerated. The
Company plans to re-submit the Amphora New Drug Application (NDA)
in the fourth quarter of 2019.
The Company expects to report top-line data in the fourth
quarter of 2019 from AMPREVENCE, the double-blinded
placebo-controlled Phase 2b clinical
trial of Amphora to prevent urogenital acquisition of Chlamydia
trachomatis (primary endpoint) and Neisseria gonorrhea
(secondary endpoint) in women. This study enrolled approximately
850 women at approximately 50 centers in the United
States. There are currently no therapeutics approved for the
prevention of either STI.
Amphora® is a registered trademark and MVP-R™ is a
trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements related to the timing of the planned NDA
Amphora re-submission for prevention of pregnancy, potential FDA
approval of Amphora, and the potential commercial launch of
Amphora, the anticipated results of the Phase 2b clinical
trial of Amphora to prevent urogenital acquisition
of Chlamydia trachomatis and Neisseria
gonorrhea in women, and any expected completion date or
general timing for this clinical trial. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from those, express or implied, in
these forward-looking statements. Important factors that could
impair the value of Evofem Biosciences' assets and business are
disclosed in the risk factors contained in its Annual Report on
Form 10-K filed with the Securities and Exchange
Commission and subsequent filings. All forward-looking
statements are expressly qualified in their entirety by such
factors. Evofem Biosciences does not undertake any duty to update
any forward-looking statement except as required by law.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
M: (917) 673-5775
Media Contact
Greg
Jawski
Porter Novelli
Greg.jawski@porternovelli.com
M: (917) 749-4964
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2019-results-and-provide-corporate-update-on-august-6-2019-300892886.html
SOURCE Evofem Biosciences, Inc.